GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR SignalingSummary
Background & Aims: Glucagon-like peptide (GLP)-2 may exert antifibrotic effects on hepatic stellate cells (HSCs). Thus, we aimed to test whether application of the GLP-2 analogue teduglutide has hepatoprotective and antifibrotic effects in the Mdr2/Abcb4-/- mouse model of sclerosing cholangi...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Cellular and Molecular Gastroenterology and Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352345X23001479 |
| _version_ | 1827808330251239424 |
|---|---|
| author | Claudia D. Fuchs Thierry Claudel Veronika Mlitz Alessandra Riva Moritz Menz Ksenia Brusilovskaya Felix Haller Maximilian Baumgartner Philipp Königshofer Lukas W. Unger Wilhelm Sjöland Hubert Scharnagl Tatjana Stojakovic Georg Busslinger Thomas Reiberger Hanns-Ulrich Marschall Michael Trauner |
| author_facet | Claudia D. Fuchs Thierry Claudel Veronika Mlitz Alessandra Riva Moritz Menz Ksenia Brusilovskaya Felix Haller Maximilian Baumgartner Philipp Königshofer Lukas W. Unger Wilhelm Sjöland Hubert Scharnagl Tatjana Stojakovic Georg Busslinger Thomas Reiberger Hanns-Ulrich Marschall Michael Trauner |
| author_sort | Claudia D. Fuchs |
| collection | DOAJ |
| description | Background & Aims: Glucagon-like peptide (GLP)-2 may exert antifibrotic effects on hepatic stellate cells (HSCs). Thus, we aimed to test whether application of the GLP-2 analogue teduglutide has hepatoprotective and antifibrotic effects in the Mdr2/Abcb4-/- mouse model of sclerosing cholangitis displaying hepatic inflammation and fibrosis. Methods: Mdr2-/- mice were injected daily for 4 weeks with teduglutide followed by gene expression profiling (bulk liver; isolated HSCs) and immunohistochemistry. Activated HSCs (LX2 cells) and immortalized human hepatocytes and human intestinal organoids were treated with GLP-2. mRNA profiling by reverse transcription polymerase chain reaction and electrophoretic mobility shift assay using cytosolic and nuclear protein extracts was performed. Results: Hepatic inflammation, fibrosis, and reactive cholangiocyte phenotype were improved in GLP-2-treated Mdr2-/- mice. Primary HSCs isolated from Mdr2-/- mice and LX2 cells exposed to GLP-2 in vitro displayed significantly increased mRNA expression levels of NR4a1/Nur77 (P < .05). Electrophoretic mobility shift assay revealed an increased nuclear NR4a1 binding after GLP-2 treatment in LX2 cells. Moreover, GLP-2 alleviated the Tgfβ-mediated reduction of NR4a1 nuclear binding activity. In vivo, GLP-2 treatment of Mdr2-/- mice resulted in increased intrahepatic levels of muricholic acids (accordingly Cyp2c70 mRNA expression was significantly increased), and in reduced mRNA levels of Cyp7a1 and FXR. Serum Fgf15 levels were increased in Mdr2-/- mice treated with GLP-2. Accordingly, GLP-2 treatment of human intestinal organoids activated their FXR-FGF19 signaling axis. Conclusions: GLP-2 treatment increased NR4a1/Nur77 activation in HSCs, subsequently attenuating their activation. GLP-2 promoted intestinal Fxr-Fgf15/19 signaling resulting in reduced Cyp7a1 and increased Cyp2c70 expression in the liver, contributing to hepatoprotective and antifibrotic effects of GLP-2 in the Mdr2-/- mouse model. |
| first_indexed | 2024-03-11T22:25:40Z |
| format | Article |
| id | doaj.art-38608f1e5ab54160be285257cf74e3a7 |
| institution | Directory Open Access Journal |
| issn | 2352-345X |
| language | English |
| last_indexed | 2024-03-11T22:25:40Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cellular and Molecular Gastroenterology and Hepatology |
| spelling | doaj.art-38608f1e5ab54160be285257cf74e3a72023-09-24T05:15:39ZengElsevierCellular and Molecular Gastroenterology and Hepatology2352-345X2023-01-01165847856GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR SignalingSummaryClaudia D. Fuchs0Thierry Claudel1Veronika Mlitz2Alessandra Riva3Moritz Menz4Ksenia Brusilovskaya5Felix Haller6Maximilian Baumgartner7Philipp Königshofer8Lukas W. Unger9Wilhelm Sjöland10Hubert Scharnagl11Tatjana Stojakovic12Georg Busslinger13Thomas Reiberger14Hanns-Ulrich Marschall15Michael Trauner16Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, AustriaHans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, AustriaHans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, AustriaDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, AustriaHans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, AustriaDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Vienna Experimental Hepatic Hemodynamic Lab (HEPEX), Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Portal Hypertension and Liver fibrosis, Medical University of Vienna, Vienna, AustriaDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, AustriaDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, AustriaDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Vienna Experimental Hepatic Hemodynamic Lab (HEPEX), Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Portal Hypertension and Liver fibrosis, Medical University of Vienna, Vienna, AustriaDivision of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, AustriaDepartment of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, AustriaClinical Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Graz, Graz, AustriaDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, AustriaDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Vienna Experimental Hepatic Hemodynamic Lab (HEPEX), Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Portal Hypertension and Liver fibrosis, Medical University of Vienna, Vienna, AustriaDepartment of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenHans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Correspondence Address correspondence to: Michael Trauner, MD, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.Background & Aims: Glucagon-like peptide (GLP)-2 may exert antifibrotic effects on hepatic stellate cells (HSCs). Thus, we aimed to test whether application of the GLP-2 analogue teduglutide has hepatoprotective and antifibrotic effects in the Mdr2/Abcb4-/- mouse model of sclerosing cholangitis displaying hepatic inflammation and fibrosis. Methods: Mdr2-/- mice were injected daily for 4 weeks with teduglutide followed by gene expression profiling (bulk liver; isolated HSCs) and immunohistochemistry. Activated HSCs (LX2 cells) and immortalized human hepatocytes and human intestinal organoids were treated with GLP-2. mRNA profiling by reverse transcription polymerase chain reaction and electrophoretic mobility shift assay using cytosolic and nuclear protein extracts was performed. Results: Hepatic inflammation, fibrosis, and reactive cholangiocyte phenotype were improved in GLP-2-treated Mdr2-/- mice. Primary HSCs isolated from Mdr2-/- mice and LX2 cells exposed to GLP-2 in vitro displayed significantly increased mRNA expression levels of NR4a1/Nur77 (P < .05). Electrophoretic mobility shift assay revealed an increased nuclear NR4a1 binding after GLP-2 treatment in LX2 cells. Moreover, GLP-2 alleviated the Tgfβ-mediated reduction of NR4a1 nuclear binding activity. In vivo, GLP-2 treatment of Mdr2-/- mice resulted in increased intrahepatic levels of muricholic acids (accordingly Cyp2c70 mRNA expression was significantly increased), and in reduced mRNA levels of Cyp7a1 and FXR. Serum Fgf15 levels were increased in Mdr2-/- mice treated with GLP-2. Accordingly, GLP-2 treatment of human intestinal organoids activated their FXR-FGF19 signaling axis. Conclusions: GLP-2 treatment increased NR4a1/Nur77 activation in HSCs, subsequently attenuating their activation. GLP-2 promoted intestinal Fxr-Fgf15/19 signaling resulting in reduced Cyp7a1 and increased Cyp2c70 expression in the liver, contributing to hepatoprotective and antifibrotic effects of GLP-2 in the Mdr2-/- mouse model.http://www.sciencedirect.com/science/article/pii/S2352345X23001479FibrosisBile Acid HomeostasisNuclear BindingFGF15/19 |
| spellingShingle | Claudia D. Fuchs Thierry Claudel Veronika Mlitz Alessandra Riva Moritz Menz Ksenia Brusilovskaya Felix Haller Maximilian Baumgartner Philipp Königshofer Lukas W. Unger Wilhelm Sjöland Hubert Scharnagl Tatjana Stojakovic Georg Busslinger Thomas Reiberger Hanns-Ulrich Marschall Michael Trauner GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR SignalingSummary Cellular and Molecular Gastroenterology and Hepatology Fibrosis Bile Acid Homeostasis Nuclear Binding FGF15/19 |
| title | GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR SignalingSummary |
| title_full | GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR SignalingSummary |
| title_fullStr | GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR SignalingSummary |
| title_full_unstemmed | GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR SignalingSummary |
| title_short | GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR SignalingSummary |
| title_sort | glp 2 improves hepatic inflammation and fibrosis in mdr2 mice via activation of nr4a1 nur77 in hepatic stellate cells and intestinal fxr signalingsummary |
| topic | Fibrosis Bile Acid Homeostasis Nuclear Binding FGF15/19 |
| url | http://www.sciencedirect.com/science/article/pii/S2352345X23001479 |
| work_keys_str_mv | AT claudiadfuchs glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT thierryclaudel glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT veronikamlitz glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT alessandrariva glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT moritzmenz glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT kseniabrusilovskaya glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT felixhaller glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT maximilianbaumgartner glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT philippkonigshofer glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT lukaswunger glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT wilhelmsjoland glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT hubertscharnagl glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT tatjanastojakovic glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT georgbusslinger glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT thomasreiberger glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT hannsulrichmarschall glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary AT michaeltrauner glp2improveshepaticinflammationandfibrosisinmdr2miceviaactivationofnr4a1nur77inhepaticstellatecellsandintestinalfxrsignalingsummary |